
---
title: '通化东宝：超速效赖脯胰岛素注射液中国III期临床试验完成首例受试者入组'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=9600'
author: 证券时报网
comments: false
date: Mon, 09 May 2022 15:42:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=9600'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600867" style="color: #2f67d1;text-decoration: none;" code="600867" target="_blank">通化东宝</a>(600867)5月9日晚间公告，超速效赖脯胰岛素注射液（THDB0206注射液）中国III期临床试验完成首例受试者入组。</p>

                  
</div>
            